Multi-drug-resistant tuberculosis overview: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Multi-drug-resistant tuberculosis}} | {{Multi-drug-resistant tuberculosis}} | ||
{{CMG}}; {{AE}} {{AL | {{CMG}}; {{AE}} {{AL}}; {{Ammu}} | ||
==Overview== | ==Overview== |
Revision as of 12:52, 29 September 2014
Multi-drug-resistant tuberculosis Microchapters |
Differentiating Multi-drug-resistant tuberculosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Multi-drug-resistant tuberculosis overview On the Web |
American Roentgen Ray Society Images of Multi-drug-resistant tuberculosis overview |
Directions to Hospitals Treating Multi-drug-resistant tuberculosis |
Risk calculators and risk factors for Multi-drug-resistant tuberculosis overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]; Ammu Susheela, M.D. [3]
Overview
Multi-drug resistant tuberculosis (MDR-TB) is defined as TB that is resistant at least to isoniazid (INH) and rifampicin (RMP). Isolates that are multiply-resistant to any other combination of anti-TB drugs but not to INH and RMP are not classed as MDR-TB.